Antisense therapy uses synthetic genetic code to silence disease-causing messages within our cells.
In short: Antisense oligonucleotides act like molecular editors, intercepting the instructions our cells use to build proteins. By targeting specific RNA sequences, these synthetic chains can block harmful proteins or correct splicing errors, offering a precise way to treat conditions ranging from rare genetic disorders to complex metabolic diseases.
Antisense technology works by introducing short, synthetic strands of nucleic acids designed to bind to specific messenger RNA (mRNA) sequences. Once bound, these antisense oligonucleotides (ASOs) can alter gene expression through several mechanisms, such as triggering the degradation of the target RNA or physically blocking the cellular machinery from translating it. This approach allows researchers to intervene at the RNA level, effectively silencing the production of proteins that drive disease.
The journey of an ASO from injection to its target is complex. Research has revealed that these molecules rely on specific cellular receptors, such as CD44, to enter cells via endocytosis. Once inside, they must navigate endosomal pathways to reach the nucleus or cytoplasm. Recent studies suggest that the interaction between ASOs and proteins like EPHA2 can promote the formation of leaky endosomes, which facilitates the release of the therapeutic agent into the cell, where it can finally perform its function.
The evolution of ASOs has progressed through three generations of chemical modifications designed to improve stability and efficacy. Early versions were prone to degradation, but modern designs incorporate phosphorothioate linkages and sugar modifications to extend their half-life and allow for systemic delivery without needing complex vehicles. Newer advancements, such as GalNAc-conjugation, have further refined this process, enabling targeted delivery to specific organs like the liver, as seen in treatments for hypertriglyceridemia.
While these therapies hold immense promise, they also present unique challenges. Because ASOs are highly specific, they can be tailored to individual mutations, as demonstrated by the development of milasen for a single patient. However, safety remains a priority, as some intrathecally delivered treatments have been associated with unexpected side effects like ventricular enlargement. As the field matures, the focus is shifting toward optimizing delivery routes and minimizing off-target effects to ensure these genetic medicines are both safe and effective.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Antisense technology: an overview and prospectus - Nature Reviews Drug Discovery
- Also: Antisense therapy
- Also: EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery.
- Also: Olezarsen: A Next-Generation Antisense Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome.
To cite this card, link to https://intellectplus.co.uk/app/health-antisense-therapy.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Drugs and medication · More in Health · Latest · A–Z · All topics
